HROW Key Statistics, Chart & Performance
The current stock price of HROW is 46.78 USD. In the past month the price decreased by -6.81%. In the past year, price increased by 27.57%.
HROW Latest News, Press Relases and Analysis
HROW Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About HROW
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Company Info
HARROW INC
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE 37205 US
CEO: Mark L. Baum
Employees: 382
Phone: 16157334731
HARROW INC / HROW FAQ
Can you describe the business of HARROW INC?
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Can you provide the latest stock price for HARROW INC?
The current stock price of HROW is 46.78 USD. The price decreased by -8.35% in the last trading session.
What is the dividend status of HARROW INC?
HROW does not pay a dividend.
What is the ChartMill technical and fundamental rating of HROW stock?
HROW has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is HARROW INC (HROW) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HROW.
Can you provide the growth outlook for HARROW INC?
The Revenue of HARROW INC (HROW) is expected to grow by 39.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of HROW stock?
HARROW INC (HROW) has a market capitalization of 1.73B USD. This makes HROW a Small Cap stock.
HROW Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 84.61% of all stocks.
HROW Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HROW. HROW has an average financial health and profitability rating.
HROW Financial Highlights
Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 109.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.37% | ||
| ROE | -10.6% | ||
| Debt/Equity | 5.17 |
HROW Forecast & Estimates
14 analysts have analysed HROW and the average price target is 72.13 USD. This implies a price increase of 54.19% is expected in the next year compared to the current price of 46.78.
For the next year, analysts expect an EPS growth of 123.84% and a revenue growth 39.77% for HROW